(Q34444955)

2 August 2017

title

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

1 reference

Yves Horsmans

1

1 reference

2 August 2017

Thomas Berg

2

1 reference

2 August 2017

Jean-Pierre Desager

3

1 reference

2 August 2017

Tobias Mueller

4

1 reference

2 August 2017

Eckart Schott

5

1 reference

2 August 2017

Simon P Fletcher

6

1 reference

2 August 2017

Kevin R Steffy

7

1 reference

2 August 2017

Lisa A Bauman

8

1 reference

2 August 2017

Bradley M Kerr

9

1 reference

2 August 2017

Devron R Averett

10

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

2 August 2017

1 reference

2 August 2017

volume

42

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

724-731

1 reference

Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent

2 August 2017

cites work

1 reference

IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

7 January 2021

1 reference

7 January 2021

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002)

1 reference

7 January 2021

The natural history of chronic hepatitis C infection.

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.

1 reference

7 January 2021

Evasive maneuvers by hepatitis C virus

1 reference

7 January 2021

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

1 reference

7 January 2021

Innate immune recognition

1 reference

7 January 2021

Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system

1 reference

7 January 2021

Inferences, questions and possibilities in Toll-like receptor signalling

1 reference

7 January 2021

Immunology. After the toll rush

1 reference

7 January 2021

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

1 reference

7 January 2021

The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily

1 reference

7 January 2021

Recognition of pathogen-associated molecular patterns by TLR family

1 reference

7 January 2021

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

1 reference

7 January 2021

Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents

1 reference

7 January 2021

Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice

1 reference

7 January 2021

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

1 reference

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

7 January 2021

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

1 reference

7 January 2021

Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.

1 reference

7 January 2021

Activity and tolerance of a continuous subcutaneous infusion of interferon-alpha2b in patients with chronic hepatitis C

1 reference

7 January 2021

Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients

1 reference

7 January 2021

Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection

1 reference

7 January 2021

Neopterin as a marker for immune system activation

1 reference

7 January 2021

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

1 reference

7 January 2021

The role of ribavirin-induced mutagenesis in HCV therapy: A concept or a fact?

1 reference

7 January 2021

Immunopharmacology of CpG oligodeoxynucleotides and ribavirin

1 reference

7 January 2021

Antiviral drugs in current clinical use.

1 reference

7 January 2021

A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy

1 reference

7 January 2021

The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans

1 reference

7 January 2021

Toll-like receptors as potential therapeutic targets for multiple diseases

1 reference

7 January 2021

Novel therapeutic strategies based on toll-like receptor signaling

1 reference

7 January 2021

Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases.

1 reference

7 January 2021

Imiquimod as a dermatological therapy

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20839

1 reference

2 August 2017

1 reference